Tecan Group AG : Tecan publishes 2012 Annual Report and notice of its Annual
Tecan Group AG / Tecan publishes 2012 Annual Report and notice of its Annual
General Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer
is solely responsible for the content of this announcement.
Männedorf, Switzerland, March 27, 2013 - The Tecan Group (SIX Swiss Exchange:
TECN) today announced the publication of its 2012 Annual Report in the
Investor Relations section of the company's website at www.tecan.com. An iPad
App for the Tecan Financial Reports is available from the App Store. Tecan
already published its 2012 financial results in a press release and at the
Press Briefing on Annual Results and Analysts' Conference held on March 7,
2013. Today also saw the publication and dispatch of the notice of the Annual
General Meeting of the Tecan Group AG. The Annual General Meeting will take
place on April 17, 2013. The notice is also published on the company's
Further increase in distribution to shareholders
On the basis of a strong balance sheet and a sustainable good business
outlook, Tecan intends to increase its profit distribution to shareholders
again. The Board of Directors will therefore propose a 20% increase in the
dividend from CHF1.25 to CHF1.50 per share to the shareholders at the
Company's Annual General Meeting on April 17, 2013. The dividend will be paid
out in part from the available capital contribution reserve, and this portion
of CHF 1.00 is therefore not subject to withholding tax.
Election to the Board of Directors
As previously announced, the Board of Directors will propose the election of
Dr. Christa Kreuzberg as a new member of the Board at the Annual General
Meeting. Dr. Kreuzburg is an experienced manager from the pharma industry, and
has held a range of management positions at Bayer AG. Most recently, she was a
member of the Executive Committee of Bayer HealthCare and Head of Bayer
Schering Pharma Europe/Canada.
The Board will also propose the reelection of current members Rolf A. Classon,
Heinrich Fischer, Dr. Oliver S. Fetzer, Gérard Vaillant, Erik Walldén and Dr.
Karen Huebscher for a further one-year term. Dominique F. Baly will not seek
reelection at this year's Annual General Meeting.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments
and solutions in biopharmaceuticals, forensics and clinical diagnostics. The
company specializes in the development, production and distribution of
automated workflow solutions for laboratories in the life sciences sector. Its
clients include pharmaceutical and biotechnology companies, university
research departments, forensic and diagnostic laboratories. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM instruments and components that are then distributed by
partner companies. Founded in Switzerland in 1980, the company has
manufacturing, research and development sites in both Europe and North America
and maintains a sales and service network in 52 countries. In 2012, Tecan
generated sales of CHF391million (USD416million; EUR323million).
Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN;
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Press Release (PDF)
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
--- End of Message ---
Tecan Group AG
Seestrasse 103 Männedorf Switzerland
Press spacebar to pause and continue. Press esc to stop.